Keywords: USP, WHO, Antimalarials, Substandard, Madagascar, Senegal, Uganda
USP-WHO study finds a third of antimalarials sampled in three African nations to be substandard
Article | 09 February 2010
The first results from a large-scale study of key antimalarial medicines in 10 sub-Saharan African countries reveal that a high percentage ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
